Rep. Cisneros Discloses Sale of Kenvue Shares in July Transaction

WASHINGTON — Representative Gilbert Ray Cisneros, Jr. disclosed a transaction involving shares of personal care products company Kenvue Inc. on Tuesday, revealing he sold stock between $1,001 and $15,000 on July 17. The disclosure, filed with the U.S. House of Representatives ethics office, marks the latest in a series of financial reports submitted by members of Congress regarding their personal investment portfolios.

The transaction involved Kenvue Inc., which trades on the New York Stock Exchange under the ticker symbol KVUE. The company was spun off from Johnson & Johnson in 2023 and holds major consumer brands including Band-Aid, Neutrogena, and Listerine. Under federal ethics rules, members of Congress must report stock transactions within 45 days of execution, providing a range for the value rather than exact figures to protect privacy while maintaining transparency.

Cisneros, representing a district in Texas, did not specify the number of shares sold or the precise price per share in the filing. The reported range indicates the total value of the trade fell somewhere between just over $1,000 and $15,000. Such disclosures are standard procedure for lawmakers who hold equities in public companies, particularly those that may be subject to federal regulation or legislative oversight.

The timing of the sale occurred more than two months prior to the filing date, consistent with the statutory deadline for reporting. No immediate statement was released by Cisneros' office regarding the rationale behind the divestment. The representative's portfolio disclosure did not indicate whether the shares were purchased recently or held as part of a long-term investment strategy.

Kenvue stock has experienced volatility in recent market cycles, influenced by broader consumer discretionary trends and changes in retail demand. While the sale does not inherently suggest insider knowledge or conflict of interest, it draws attention to the intersection of legislative duties and personal financial interests. Ethics watchdogs often scrutinize such filings to ensure that trading patterns do not align suspiciously with pending legislation affecting the company's sector.

The filing provides no information regarding whether Cisneros intends to repurchase shares in the future or if this transaction represents a complete exit from the position. As of Tuesday, there were no indications of an investigation into the trade by congressional ethics committees or federal authorities.

Questions remain regarding the specific circumstances surrounding the decision to liquidate the position during July. Whether the sale was part of a routine portfolio rebalancing or driven by other factors has not been addressed publicly. The transaction will now be part of the permanent public record, accessible for review by constituents and oversight groups monitoring congressional financial activities.